Regeneron’s Blood Cancer Therapy Faces Setback as FDA Raises Trial Concerns

Source link :

(Reuters) -Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma, raising concerns over the progress of ongoing confirmatory trials. In its so-called complete response letter (CRL), the U.S. Food and Drug Administration said it needed more data from enrollments in dose-finding and confirmatory […]

Author : News Health

Publish date : 2024-03-25 11:29:54

Copyright for syndicated content belongs to the linked Source.